There is no validated dose for the Wolverine blend — only single-compound animal numbers

BPC-157 TB-500 Dosage in the Research Literature

BPC-157 TB-500 dosage has no validated basis. There is no peer-reviewed combination dose-finding study, no established blend ratio, and no validated human dose for the pair ^[6][7]. Everything below describes what was administered to which species at which dose in the underlying single-compound studies — it is research context, not human-use guidance, and this page recommends nothing.

Commercial research-product labeling commonly pairs BPC-157 and TB-500 at fixed combined masses per vial — for example ~10 mg plus ~10 mg, or a 20 mg combined vial — but those numbers are product packaging, not a studied dose. In the underlying animal work, the BPC-157 component was frequently dosed per body weight at ~10 µg/kg and ~10 ng/kg, with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats ^[1]. The TB-500 / Thymosin Beta-4 component spans a wide range — for instance 2-18 mg/kg intraperitoneally in a rat embolic-stroke dose-response study — and 150 µg twice weekly for six months in the mdx muscular-dystrophy study ^[4]. None of these is a human dose, and none was given as the blend.

The only human reference points come from full-length Thymosin Beta-4, not the TB-500 fragment and not the pair: intravenous Thymosin Beta-4 was reported well tolerated up to 1260 mg in early safety work, and a later first-in-human study used single doses around 25 µg/kg and 5 µg/kg daily for ten days ^[4][5]. Those are single-agent safety reference points for a different molecule, cited here only to be clear about what human numbers do and do not exist. There is no human BPC-157 TB-500 dose to report, and this page does not construct one.

Half-life, routes, and the non-monotonic dose-response

Half-life of BPC-157 and TB-500

BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study. No validated human half-life exists for the TB-500 heptapeptide; human IV full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics ^[4][5]. No validated half-life exists for the blend.

BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog pharmacokinetic study; no validated human half-life exists for the TB-500 heptapeptide, and none exists for the blend. Human intravenous full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but that is the full-length protein, not the Ac-LKKTETQ 7-mer ^[4][5].

The dose-response data carry a specific warning for the 'more is better' loading logic that circulates online. In the rat embolic-stroke study, Thymosin Beta-4 dosing was non-monotonic — a modeled optimum near 3.75 mg/kg, while 18 mg/kg gave no benefit ^[4]. A higher dose was not a better dose. Routes studied across the single-compound literature include intraperitoneal (predominant in the rodent efficacy work), subcutaneous and intramuscular (the predominant research-community routes, not from controlled human efficacy trials), intravenous (human Phase 1 of full-length Thymosin Beta-4; a BPC-157 IV safety pilot), and local or topical application in individual-compound wound and tendon models.

<a id="oral-vs-injectable"></a>

Oral vs Injectable Routes for BPC-157 and TB-500 in Studies

BPC-157 is studied as a 'stable gastric' peptide and has been administered perorally in animal work, while the predominant research-community route for the blend is injection ^[1]. Oral blend products are marketed but lack validated pharmacokinetics; there is no controlled human bioavailability data for an oral BPC 157 TB 500 product.

Reconstitution, frequency, and cycling — described, not prescribed

Reconstitution practice for the blend

Research peptides are supplied as lyophilized powder and reconstituted in bacteriostatic or sterile water, then refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed ^[5]. This is described for research handling, not as human-use guidance.

Injection frequency in the literature

There is no validated injection schedule for the blend. The underlying animal studies used per-body-weight intraperitoneal dosing — BPC-157 around 10 µg/kg, full-length Thymosin Beta-4 in mg/kg ranges ^[1][4]. Community 'loading then maintenance' protocols have no controlled-trial basis.

Cycling and 'loading' protocols

Fixed-ratio vials and 'loading then maintenance' cycles circulate in the community but have no basis in controlled human trials. The rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — a high dose gave no benefit ^[4] — which directly undercuts 'more is better' loading logic.

<a id="community-discussion"></a>

What Research-Community Discussion Gets Right and Wrong

Discussion of BPC-157 TB-500 on Reddit and similar forums gets the broad mechanism story roughly right — two repair peptides, angiogenesis, actin — but routinely overstates the evidence, presenting community 'protocols' and dramatic recovery claims as if validated. The published evidence is preclinical, single-compound, and largely from animal models ^[6][7][8]; no controlled human combination data exist. The reliable parts are the single-compound mechanisms; the unreliable parts are the doses, ratios, and outcome promises.